Scarica l'app Stockscreener
14.21
2.27%
-0.33
Dopo l'orario di chiusura:
14.21
Precedente Chiudi:
$14.54
Aprire:
$14.4
Volume 24 ore:
41,591
Relative Volume:
0.43
Capitalizzazione di mercato:
$2.56B
Reddito:
$420.26M
Utile/perdita netta:
$-41.97M
Rapporto P/E:
-56.84
EPS:
-0.25
Flusso di cassa netto:
$-65.34M
1 W Prestazione:
-5.27%
1M Prestazione:
+11.19%
6M Prestazione:
-20.84%
1 anno Prestazione:
-31.75%
Intervallo 1D:
$14.19
$14.70
Intervallo di 1 settimana:
$14.18
$15.20
Portata 52W:
$11.51
$21.92
Hutchmed China Limited Adr Stock (HCM) Company Profile
Confronta HCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
14.21 | 2.56B | 420.26M | -41.97M | -65.34M | -0.25 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-24 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-05-04 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-08-03 | Iniziato | Jefferies | Buy |
| 2020-10-02 | Iniziato | Deutsche Bank | Buy |
| 2020-03-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-20 | Iniziato | Goldman | Buy |
| 2019-11-19 | Iniziato | CLSA | Buy |
| 2019-10-23 | Reiterato | BofA/Merrill | Buy |
| 2019-07-05 | Iniziato | Macquarie | Outperform |
Mostra tutto
Hutchmed China Limited Adr Borsa (HCM) Ultime notizie
UPDATEInternational companies to host live webcasts at - GlobeNewswire
International companies to host live webcasts at Deutsche - GlobeNewswire
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com
Marshall Wace LLP Acquires New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - The AM Reporter
RCSHutchmed China LtdHUTCHMEDData to be Presented at AACR 2025 - TradingView
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - Yahoo Finance
HUTCHMEDOncology portfolio growth expected to continue - Research Tree
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewswire Inc.
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewswire
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire
Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 - AsiaOne
HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance
Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance
CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs - AASTOCKS.com
ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
Sea Limited Sponsored ADR (SE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com
HUTCHMED Announces NMPA Full Approval for - GlobeNewswire
UBS Trims HUTCHMED (00013.HK)TP to $38.7 w/ Rating Buy - AASTOCKS.com
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast
Market news - Research the market
Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification - OncLive
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire
Jane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp - Defense World
HCMHUTCHMED (China) Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces Breakthrough Therapy Designation in - GlobeNewswire
Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast
Why Alibaba Group Holding Limited (BABA) Is One of the Best ADR Stocks to Invest in? - Yahoo Finance
M&G Plc Has $5.35 Million Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
How Trump and Harris plan to address housing affordability - Yahoo Finance
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® - GlobeNewswire
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful - The Bakersfield Californian
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - Yahoo Finance
HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ... - Yahoo Finance
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - Yahoo Finance
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - Yahoo Finance
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Yahoo Finance
Dr Mehta on the Sequencing of CAR T-Cell Therapy and Bispecific Antibodies in Lymphoma - OncLive
What Starbucks' new CEO must instantly do to address crisis - Yahoo Finance
Hutchmed China Limited Adr Azioni (HCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.82%
1.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):